Skip to main content

Quince Therapeutics, Inc.

corporate_fare Company Profile

Quince Therapeutics, Inc.

QNCX·NASDAQ·Life Sciences·CIK 0001662774

Quince Therapeutics, Inc. is a biotechnology company that previously focused its development activities on treating rare diseases using a patient's own biology. The company's proprietary AIDE technology platform is an innovative drug/device combination designed to automatically encapsulate a drug into a patient's own red blood cells. This technology aimed to leverage the characteristics of red blood cells for drug delivery, potentially offering benefits such as improved safety and tolerability, enhanced tissue biodistribution, reduced immunogenicity, and prolonged circulating half-life. The AIDE platform was designed to apply to a wide range of small or large molecule drugs and biologics. The company's lead asset, eDSP, utilized the AIDE technology to encapsulate DSP into a patient's red blood cells. In January 2026, Quince Therapeutics completed its pivotal Phase 3 NEAT clinical trial, which evaluated eDSP for the treatment of A-T, a rare pediatric neurodegenerative disease. The primary endpoint of the NEAT study, which measured the change from baseline to the last efficacy visit at month six using the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo, did not achieve statistical significance. Consequently, eDSP does not appear to be an effective treatment for A-T, and the company will not continue its development for this or other therapeutic indications. Quince Therapeutics currently has no other product candidates and lacks sufficient resources to pursue further research and development activities. The company is focused on preserving cash while evaluating strategic alternatives. On February 9, 2026, LifeSci Capital was engaged as the exclusive financial advisor to assist with restructuring activities and the evaluation of strategic alternatives.

Quince Therapeutics, Inc. (NASDAQ:QNCX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 36 items for QNCX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Quince Therapeutics Amends 8-K to Clarify Positive LAM-001 Phase 2a Efficacy Data
  • Quince Therapeutics Acquires Orphai, Secures $115M Upfront Financing to Fund New Pulmonary Pipeline
  • Quince Therapeutics Posts $35.9M Q1 Profit, Reversing Prior Going Concern Doubts
  • Quince Therapeutics Reports Q1 Net Income from Restructuring, Raises $20.4M via Highly Dilutive ATM Amid Ongoing Going Concern Doubts
  • Quince Regains Nasdaq Bid-Price Compliance; $50M MVLS Deficiency Remains
$31.73
52-week range · as of 2026-10-09 $15.1 – $909.98
Market cap
$32.27M
Volume
138.7K (5.2× avg)
3-mo avg 26.7K
Last traded · 2026-10-12

show_chartPrice Chart

Loading chart...

feed QNCX - Filings & News (Page 2)

QNCX
May 18, 2026, 4:20 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $1.01
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
May 18, 2026, 9:33 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.950
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
May 11, 2026, 5:11 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.26
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
May 11, 2026, 5:09 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.24
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Apr 28, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.21
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Apr 28, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Apr 27, 2026, 4:41 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $1.28
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Apr 27, 2026, 4:39 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $1.28
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Apr 17, 2026, 5:25 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $1.36
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Apr 10, 2026, 4:35 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.1207
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Apr 09, 2026, 9:23 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1577
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Mar 30, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.1247
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Mar 20, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.0871
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Feb 12, 2026, 6:06 AM EST
Filing Type: 8-K
Importance Score:
10
Price at Filing: $0.5176
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Feb 02, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.180
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
QNCX
Jan 29, 2026, 4:40 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2801
Real-time Price: $31.73 info
Change: Reverse Stock Split info
Market Cap: $32.271M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets